002030 Stock Overview
Researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 002030 from our risk checks.
Daan Gene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.05 |
| 52 Week High | CN¥11.00 |
| 52 Week Low | CN¥4.93 |
| Beta | 0.56 |
| 11 Month Change | -19.46% |
| 3 Month Change | -35.75% |
| 1 Year Change | -49.20% |
| 33 Year Change | -74.60% |
| 5 Year Change | -15.51% |
| Change since IPO | 444.49% |
Recent News & Updates
Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?
May 02
Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 05Recent updates
Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?
May 02Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 05Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)
Mar 25Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Mar 06Shareholder Returns
| 002030 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.3% | 0.007% | 0.6% |
| 1Y | -49.2% | -24.2% | -18.5% |
Return vs Industry: 002030 underperformed the CN Biotechs industry which returned -23.3% over the past year.
Return vs Market: 002030 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 002030 volatility | |
|---|---|
| 002030 Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002030's share price has been volatile over the past 3 months.
Volatility Over Time: 002030's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,968 | Luo Huang | www.daangene.com |
Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables. The company offers fluorescence quantitative PCR products, enzyme-linked immunoassay products, instrument products, and scientific research service products. It also provides medical examination, and health consultation and management services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services.
Daan Gene Co., Ltd. Fundamentals Summary
| 002030 fundamental statistics | |
|---|---|
| Market cap | CN¥7.14b |
| Earnings (TTM) | -CN¥295.19m |
| Revenue (TTM) | CN¥1.04b |
6.8x
P/S Ratio-24.0x
P/E RatioIs 002030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002030 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.04b |
| Cost of Revenue | CN¥737.81m |
| Gross Profit | CN¥300.35m |
| Other Expenses | CN¥595.55m |
| Earnings | -CN¥295.19m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 31, 2024
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 28.93% |
| Net Profit Margin | -28.43% |
| Debt/Equity Ratio | 3.7% |
How did 002030 perform over the long term?
See historical performance and comparison